Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects
Phase 1 Study of Anti-glycation Agent GLY-230
To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.
No drug administered
Inclusion Criteria: Men age 18-55 Negative drug screen Normal EKG, clinical chemistries, CBC, urinalysis, and Give written informed consent Exclusion Criteria: Active concomitant serious medical or surgical disease, Hepatic or renal laboratory values above reference range, ise of other experimental drug within previous 30 days